TY - JOUR
T1 - Clinical proteomics
T2 - Translating benchside promise into bedside reality
AU - Petricoin, Emanuel F.
AU - Zoon, Kathryn C.
AU - Kohn, Elise C.
AU - Barrett, J. Carl
AU - Liotta, Lance A.
PY - 2002/9
Y1 - 2002/9
N2 - The ultimate goal of proteomics is to characterize the information flow through protein networks. This information can be a cause, or a consequence, of disease processes. Clinical proteomics is an exciting new subdiscipline of proteomics that involves the application of proteomic technologies at the bedside, and cancer, in particular, is a model disease for studying such applications. Here, we describe proteomic technologies that are being developed to detect cancer earlier, to discover the next generation of targets and imaging biomarkers, and finally to tailor the therapy to the patient.
AB - The ultimate goal of proteomics is to characterize the information flow through protein networks. This information can be a cause, or a consequence, of disease processes. Clinical proteomics is an exciting new subdiscipline of proteomics that involves the application of proteomic technologies at the bedside, and cancer, in particular, is a model disease for studying such applications. Here, we describe proteomic technologies that are being developed to detect cancer earlier, to discover the next generation of targets and imaging biomarkers, and finally to tailor the therapy to the patient.
UR - http://www.scopus.com/inward/record.url?scp=0036718796&partnerID=8YFLogxK
U2 - 10.1038/nrd891
DO - 10.1038/nrd891
M3 - Review article
C2 - 12209149
AN - SCOPUS:0036718796
SN - 1474-1776
VL - 1
SP - 683
EP - 695
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 9
ER -